Unum therapeutics inc. (UMRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-26,236

-31,833

-42,736

-40,981

-39,488

-34,532

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

1,258

1,293

1,331

1,343

1,337

1,321

1,276

1,246

1,207

1,171

0

0

0

Stock-based compensation expense

3,284

3,241

3,301

3,373

3,335

3,088

2,646

2,085

1,520

1,341

0

0

0

Realized loss on sales of marketable securities

-

-

0

0

0

-

-

-

-

-

-

-

-

Noncash consideration received from a customer

0

-

-

-

-

-

-

-

-

-

-

-

-

Premiums paid on marketable securities

-

-

-

-

-

-

-

-

-

13

0

0

0

Net amortization (accretion) of premiums (discounts) on marketable securities

-

53

142

262

299

246

152

27

-19

-17

0

0

0

Non-cash interest expense

-

-

-

-

-

23

22

22

21

20

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

-2,040

332

-539

290

439

838

-92

-56

714

-98

0

0

0

Prepaid expenses and other current assets

405

8

263

-157

-401

250

132

841

720

237

0

0

0

Operating lease, right-of-use asset

-1,387

-1,365

0

0

0

-

-

-

-

-

-

-

-

Other assets

-427

427

428

427

427

419

0

0

0

-

-

-

-

Accounts payable

-1,208

1,664

791

5

-657

367

-1,123

32

1,371

-31

0

0

0

Accrued expenses and other current liabilities

56

1,760

1,043

3,214

4,487

2,883

0

0

0

-

-

-

-

Accrued expenses and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

0

0

Deferred rent

-

-

-

-

-

-52

-40

-27

-14

-2

0

0

0

Operating lease liability

-1,507

-1,472

0

0

0

-

-

-

-

-

-

-

-

Deferred revenue

-16,094

-16,634

-5,369

-5,534

-4,239

-3,844

0

0

0

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in operating activities

-37,889

-41,514

-42,089

-39,457

-36,026

-32,489

0

0

0

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Cash flows from investing activities:
Purchases of property and equipment

-

33

20

128

516

549

649

838

667

912

0

0

0

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

6,500

0

0

0

Proceeds from maturities and sales of marketable securities

-

22,988

37,988

47,988

46,692

37,700

27,700

23,700

23,000

21,000

0

0

0

Net cash provided by investing activities

-

23,159

38,172

47,860

-1,506

-10,531

0

0

0

-

-

-

-

Cash flows from financing activities:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of common stock upon stock option exercises

135

108

503

678

592

609

0

0

0

-

-

-

-

Proceeds from issuance of stock from employee stock purchase plan

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments of initial public offering costs

-

-

-

-

-

2,056

0

0

0

-

-

-

-

Net cash provided by financing activities

170

108

503

678

70,892

70,346

0

0

0

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-29,510

-18,247

-3,414

9,081

33,360

27,326

0

0

0

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

0

0

Supplemental disclosure of noncash investing and financing information:
Purchases of property and equipment included in accounts payable

-

-

-

-

-

-

-

0

0

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

0

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

16

32

48

65

65

0

0

0